FiercePharma, the pharmaceutical's trade publication, reported yesterday that the European Medicines Agency (EMA) was adding Guillain-Barre syndrome (GBS) as a side effect to the AstraZeneca COVID-19 shot.

This comes two months after the FDA issued a similar warning for GBS on the Johnson & Johnson's COVID-19 shots.

Two months after the FDA flagged Johnson & Johnson's COVID-19 vaccine for the rare nerve disorder Guillain-Barre syndrome (GBS) Europe's drug regulator has done the same for AstraZeneca's COVID shot.

The European Medicines Agency will now list GBS as a possible and "very rare" side effect of Vaxzevria, which is administered as a two-dose regimen.

GBS is a condition in which the immune system attacks nerves and can cause temporary paralysis and breathing problems. Along with the warning, the EMA recommends that AZ vaccine recipients should seek medical attention if they feel weakness and paralysis in the extremities. (Source.)

The paralysis is not always "temporary," however, and based on years of statistics on vaccine injuries, especially for the flu shot, the evidence suggests that it is not that "rare" at all.

If you have not yet watched the 60 Minutes show on the 1976 Swine Flu scandal that Mike Wallace covered in 1979, it is worth your time to watch it.